PMID: 9657530Jul 10, 1998Paper

Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
D Muralikrishnan, Kochupurackal P Mohanakumar

Abstract

Mice were treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 30 mg/kg i.p. twice, 16 h apart). This resulted in changes in motor performance and toxic insult of nigral neurons as evidenced by dopamine depletion in nucleus caudatus putamen. In vitro and in vivo treatment of MPTP caused the generation of hydroxyl radicals (.OH) as measured by a sensitive salicylate hydroxylation procedure. A dopamine agonist, bromocriptine (10 microM and 10 mg/kg i.p.), blocked .OH formation caused by MPTP in vitro (20 microM) and in vivo (30 mg/kg i.p.). An MPTP-induced increase in the activity of catalase and superoxide dismutase in substantia nigra on the seventh day was reduced by bromocriptine pretreatment. Bromocriptine blocked MPTP-induced behavioral dysfunction as well as glutathione and dopamine depletion, indicating its potent neuroprotective action. This study suggests that bromocriptine stimulates antioxidant mechanisms in the brain and acts as a free radical scavenger in addition to its action at dopamine receptors, thus indicating its strength as a valuable neuroprotectant.

References

Apr 1, 1978·The Journal of Pharmacy and Pharmacology·H R Bürki
Feb 1, 1975·Archives of Neurology·L M AmbaniS Murphy
Jan 1, 1991·Free Radical Biology & Medicine·B HalliwellM Ingelman-Sundberg
Mar 13, 1990·European Journal of Pharmacology·C GagnonT Di Paolo
Nov 21, 1987·Lancet·D T DexterC D Marsden
Jan 1, 1988·Psychopharmacology·D M JacksonS B Ross
Feb 15, 1988·Neuroscience Letters·F B WeihmullerJ P Bruno
Aug 5, 1985·Neuroscience Letters·S J KishO Hornykiewicz
Nov 23, 1974·British Medical Journal·D B CalneA Petrie
Mar 1, 1966·Analytical Biochemistry·V H Cohn, J Lyle
Apr 30, 1984·Biochemical and Biophysical Research Communications·K ChibaN Castagnoli
Jan 1, 1984·Methods in Enzymology·H Aebi
Dec 13, 1982·Neuroscience Letters·T L PerryS Hansen
May 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·S PrzedborskiS Fahn
Nov 17, 1994·Annals of the New York Academy of Sciences·R M WuC C Chiueh
Nov 17, 1994·Annals of the New York Academy of Sciences·C C ChiuehD L Murphy
Nov 17, 1994·Annals of the New York Academy of Sciences·J A Clemens, J A Panetta
Nov 17, 1994·Annals of the New York Academy of Sciences·K P MohanakumarC C Chiueh
Jul 1, 1994·Pharmacology & Toxicology·A FredrikssonT Archer
Jan 1, 1993·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·T OishiY Murai
Mar 1, 1994·Journal of Neurochemistry·T YoshikawaM Kondo
Aug 1, 1993·Free Radical Biology & Medicine·J D AdamsA C Leung
Jan 1, 1995·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·N AraiS Kuno

❮ Previous
Next ❯

Citations

Jun 23, 2000·Annals of the New York Academy of Sciences·E GrünblattM B Youdim
Jun 22, 2006·Neurotoxicity Research·M GerlachP Riederer
Sep 22, 2006·American Journal of Therapeutics·Sheng Chen, Weidong Le
Oct 12, 2010·CNS Drugs·Santiago Perez-Lloret, Olivier Rascol
Feb 15, 2012·Neurochemical Research·Senthilkumar S KaruppagounderMuralikrishanan Dhanasekaran
Nov 28, 2012·Journal of Neuroscience Research·Sudhakar R Subramaniam, Elizabeth M Ellis
May 3, 2014·Journal of Molecular Neuroscience : MN·Govindasamy Pushpavathi SelvakumarNamasivayam Elangovan
Apr 24, 2014·Brain : a Journal of Neurology·Veronica FrancardoM Angela Cenci
Aug 21, 2014·Evidence-based Complementary and Alternative Medicine : ECAM·Minsook YeHyunsu Bae
Feb 7, 2017·Oxidative Medicine and Cellular Longevity·W A García-SuásteguiD Silva-Adaya
Jun 23, 2001·Drugs & Aging·W D Le, J Jankovic
Dec 5, 2002·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A H V Schapira
May 14, 2005·Antioxidants & Redox Signaling·Clifford W Shults
Jul 13, 2006·Clinical and Experimental Hypertension : CHE·Paola CastriFrancesco Fornai
Apr 11, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A H V Schapira
Mar 4, 2009·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Mira PopovicSvetlana Trivic
Jul 27, 2010·International Journal of Clinical Practice·S Tsouli, S Konitsiotis
May 5, 2010·CNS Neuroscience & Therapeutics·Zsigmond Tamas Kincses, Laszlo Vecsei
Feb 22, 2011·Expert Opinion on Drug Metabolism & Toxicology·Nikoletta SzabóLászló Vécsei
Jan 8, 2017·Molecular Neurobiology·Debashis DuttaKochupurackal P Mohanakumar
Apr 1, 2003·Annals of Neurology·Anthony H V Schapira, C Warren Olanow
Jun 22, 2002·Annals of the New York Academy of Sciences·Kochupurackal P MohanakumarChuang C Chiueh
Apr 3, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Jie LiAnthony L Fink
May 2, 2001·Nature Reviews. Neuroscience·M F Beal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.